AIM: To evaluate the role of intravitreal Ranibizumab in resolution of mild vitreous hemorrhage along with macular edema in Eale’s disease. METHODOLOGY: This retrospective interventional nonrandomized study was conducted in Malda Medical College, West Bengal from January 2017 to December 2018 having included 16 eyes of 16 patients with Eale’s disease. After proper clinical evaluation and required investigations, all patients received 3 consecutive doses of intravitreal Ranibizumab at 1 month interval under topical anaesthesia and strict aseptic measures along with routine systemic and periocular steroid therapy. Patients were followed up at 1 month and 3 months after the 1st dose of injection and at each visit, best corrected visual acuity(BCVA)by standard snellen’s chart, intraocular pressure(IOP) measurement by Goldmann’s applanation tonometer, extenct of vitreous hemorrhage, central macular thickness (CMT) measurement by spectral domain optical coherence tomography(SD–OCT) were recorded. All the statistical data were then analysed using paired t test with the help of SPSS software. RESULTS: All but one patients had shown improvement in terms of resolution of vitreous hemorrhage and macular edema thus enhancing vision. CONCLUSION: Intravitreal Ranibizumab can be a credible agent to deal with mild vitreous hemorrhage and macular edema associated with Eale’s disease.